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Methods: This work integrates hosts ecology, biogeography,
omparative hosts- pathogens phylogeny to propose one hypoth-
sis about the making of the SARS-CoV ancestor. The Coronavirinae
olymerase sequence has been targeted by Rt-PCR in non-
nvasive samples from bats collected in isolated and forested area
n Thailand. A Coronavirinae phylogeny based on all available
equences have been inferred by several methods.
Results: Two new coronaviruses were detected in two Hip-
osideridae bat species in Thailand: one Betacoronavirus-b that
xhibited long-lasting infection in an isolated bat colony and one
lphacoronavirus in another colony. Interestingly, viruses detected
n Africa or in Europe are related to those that currently circulate
n South-East Asia, reminding the underlying inﬂuence of the host
hylogeny on the Coronavirinae phylogeny.
Conclusion: These ﬁndings illuminate the origin and the natu-
al history of the Rhinolophus-hosted SARS-CoV lineage by pushing
orward the hypothesis of a Betacoronavirus spill-over from Hip-
osideridae to Rhinolophidae and then from Rhinolophidae to
ivets and Human. The common ancestor of Hipposideridae and
hinolophidae families is a key taxa in the understanding of the
ctual repartition of Betacoronaviruses.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.125
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irst multicentre evaluation of serological and molecular diag-
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Background: Crimean Congo Haemorrhagic Fever (CCHF) is a
iral tick-borne disease that occurs widely in Africa, Asia, and
astern Europe. The disease can develop severe illness in humans
ith case-fatality rates as high as 50%. The emergence of CCHF
oses a serious public health threat due to its high contagious-
ess, high lethality, potential for nosocomial spread and difﬁculties
n treatment and control. A strong laboratory capacity, in particu-
ar standardized approaches for diagnostic methods, is essential to
ncrease preparedness in countries at risk. We describe the ﬁrstnfectious Diseases 16S (2012) e2–e157 e51
evaluation study of available molecular and serological methods
targeting CCHF.
Methods: Two serological tests, an enzyme-linked immunosor-
bent assay (ELISA)* and an indirect immunoﬂuorescence assay
(IFA)** and two molecular methods, a real time quantitative
reverse-transcription PCR (qRT-PCR)*** and a low-cost, low-
density array (LCD)**** were selected based on a systematic review
of the literature. Performances of the selected methods were
compared with in house reference methods employed by the 5
participating expert laboratories, using panels of archived patient
samples from geographically diverse settings.
*Vektor-Best
**Euroimmun
***Altona-Diagnostics
****Wolfel et al., 2007
Results: Sample panels included 66 sera and 54 serum RNA
extracts from patients with conﬁrmed CCHF diagnosis, and 73 sera
and 21 serum RNA extracts from febrile patients with symptoms
compatible with CCHF or from healthy individuals. When com-
pared to the reference tests, the observed sensitivity of the IgM-
and IgG-ELISA was 87.8% and 80.4%, respectively. For the IgM- and
IgG-IFA, the sensitivity was 93.9%, and 86.1%, respectively. Molec-
ular assays showed more modest sensitivities: 79.6% and 83.3% for
the qRT-PCR and LCD array, respectively. Speciﬁcity was excellent
for all assays.
Conclusion: This study demonstrated that reliable, well-
characterized serological and molecular assays and protocols are
available for CCHF diagnosis. Our results are consistent with the
ﬁnding that the application ofmolecular assays in different settings
is hampered by the high diversity of the CCHF genomes. The on-
site use of such standardized CCHF diagnostic assays by outbreak
assistance laboratories would be more time- and cost-effective,
and greatly diminish the risks posed by the handling, packaging
and shipping of highly infectious biological material to reference
laboratories abroad.
http://dx.doi.org/10.1016/j.ijid.2012.05.126
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Safety and immunogenicity of INV21, an inactivated vaccine
candidate for the prevention of hand, foot and mouth disease
caused by enterovirus 71
P. Tambyah1,∗, J. Oon1, R. Asli 1, W. Kristanto1, G. Gordon2, J.
Santangelo3, D. Stinchcomb2, C. Thomson3
1 National University Hospital, Singapore, Singapore
2 Inviragen Inc., Ft Collins, CO, USA
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Background:Hand foot andmouth disease (HFMD) is caused by
enteroviral pathogens such as enterovirus 71 (EV71). Characteris-
tically a self-limiting disease indicated by fever, mouth ulcers, and
rash, HFMD caused by EV71 can lead to viralmeningo-encephalitis,
myocarditis or poliomyelitis-like paralysis, and may be fatal. EV71
and HFMD are endemic in Asia, causing signiﬁcant morbidity, mor-
tality and economic impact in recent years. INV21 is a puriﬁed,
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cases in Nepal has come down. Due to incentive given in India, the
number of cases reporting to PHC is more than previous year.
http://dx.doi.org/10.1016/j.ijid.2012.05.12952 15th ICID Abstracts / International Journ
nactivated EV71, alum-formulated vaccine, developed to prevent
FMD caused by EV71. This study evaluated INV21 in a Phase I
linical trial in healthy adults.
Methods: Thirty-six healthy males and females aged 21 to 45
ears were enrolled into a randomised, double-blind, placebo-
ontrolled study at the Investigational Medicine Unit, National
niversity Hospital, Singapore. Subjects were enrolled to either
ow Dose [12 on INV21 (0.6 g EV71/dose); 6 on placebo] or High
ose [12 on INV21 (3g EV71/dose); 6 on placebo] group. Subjects
eceived two injections (Day 0, Day 28) intramuscularly, and were
ollowed for safety and immunogenicity assessments through Day
96.
Results: Thirty-ﬁve/36 subjects completed the study through
ay 56. Most common adverse events in INV21 and placebo sub-
ects (cough: 5/36 subjects; rhinorrhea: 5/36 subjects; pyrexia:
/36 subjects; inﬂuenza: 3/36 subjects) were mild and time-
esolved. Minimal reactions were observed at the injection site,
ith similar proﬁles seen at both dose levels. Mild (Grade 1) pain,
enderness and pruritis were reported in 1 subject in each treat-
ent group. Grade 1 erythema and induration were reported in
subject in High Dose group. No clinically signiﬁcant changes in
hemistry, haematology and urinalysis parameters were observed
n either group. Highest EV71-neutralising antibody titres were
etected 2 weeks post second dose (Day 42), with all subjects sero-
onverting (≥ 4-fold rise in titre compared to baseline) at this time
oint (Low Dose GMT = 323; High Dose GMT = 452).
Conclusion: This trial demonstrated that INV21 is a safe and
mmunogenicvaccinecandidate for thepreventionofHFMDcaused
y EV71. Future clinical trials are needed to address the ongoing
egional HFMD epidemic, and reduce mortality and morbidity.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.127
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inding a cure for HIV: The need for science, collaboration and
dvocacy
. Lewin
Monash University, Melbourne, Australia
Combination antiretroviral therapy (cART) has led to a major
eduction in HIV-related mortality and morbidity but HIV can still
ot be cured. With increasing numbers of infected people, emerg-
ng new toxicities secondary to cART and the need for life-long
reatment, there is now a real urgency to ﬁnd a cure for HIV.
Thereare currentlymultiplebarriers to curingHIV. Themost sig-
iﬁcant barrier is the establishment of a latent or “silent” infection
n resting CD4+ T cells. In latent HIV infection, the virus is able to
ntegrate into the host cell genome, but does not proceed to active
eplication. Reactivation of latently infected resting CD4+ T cells
an then re-establish infection once cART is stopped. Other signif-
cant barriers to cure include residual viral replication in patients
eceiving cART. In addition, HIV can be sequestered in long lived
ells such as macrophages and astrocytes in anatomical reservoirs,
uch as the brain, gastrointestinal tract and lymphoid tissue.
Achieving either a functional cure (long-term control of HIV
n the absence of cART) or a sterilizing cure (elimination of all
IV-infected cells) remains a major challenge. Several studies havenfectious Diseases 16S (2012) e2–e157
now demonstrated that treatment intensiﬁcation with additional
antiretrovirals (ARVs) appears to have little impact on latent reser-
voirs. One potential approach to eliminate latently infected cells is
to promote viral production in these cells. If this is done in a patient
cART, subsequent rounds of viral replication will be inhibited and
the infected cell will die.
Drugs such as histone deacetylase inhibitors and methylation
inhibitors; cytokines such as IL-7; or other activating agents includ-
ing prostratin and anti-PD-1, show promising results in reversing
latency in vitro when used either alone or in combination. In addi-
tion, gene therapy has been shown to effectively reduce expression
of the HIV co-receptor CCR5 in both animal models and ex vivo
human studies. Clinical trials using some of these approaches are
currently underway.
Recent new initiatives to fund collaborative private-public part-
nerships, enhance community engagement and deﬁne a scientiﬁc
road map for cure research are likely to signiﬁcantly accelerate
advances in the elusive path to ﬁnding a cure.
http://dx.doi.org/10.1016/j.ijid.2012.05.128
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Elimination of Kala-azar: Where do we stand in 2011?
S. Bhattacharya
SEARO/WHO, New Dehli, India
Visceral Leishmaniasis or commonly known as Kala-azar is
characterized by continued fever, loss of weight, anaemia and
splenomegaly. The disease is endemic in Bangladesh (45 districts),
India (52 districts) and Nepal (12 districts). Recently, a small focus
of Kala-azar has been reported from several districts of Bhutan.
Because of the unique epidemiology (man is the only reservoir,
Phelobotomous argentepis sand ﬂy is the only vector), IRS is effective
as vector control and oral drug Miltefosine is available. Elimina-
tion is possible in the three countries where the disease is conﬁned
in limited areas. Recently, Single injection of Lipid amphotericin B
(AmBisome) has been shown effective in 95% of cases and recom-
mended as the ﬁrst line of drug.
Since the elimination started in 2005, in the three countriesMil-
tefosine and Indoor Residual spray are available. Early diagnosis
with rK39 and treatment with Miltefosine are being done. In 2010-
11, it has beenbrought to attention that compliancewith treatment
with Miltefosine is not as expected. The feasibility of implement-
ing AmBisome at the PHC level is being explored. The number of
